Reposicionamento do ácido alfa-lipóico na esquizofrenia: ensaio clínico aberto

Abstract

Evidence from previous experimental research has demonstrated the strong relationship between oxidative imbalance and the presence of various symptoms of schizophrenia. The antioxidant properties of alpha-lipoic acid (ALA), used as a adjuvant therapy for schizophrenia, produced positive results in these same studies. The objective of this clinical study was to demonstrate the repositioning of ALA in the treatment of psychotic symptoms, as well as to promote a two-way study from a translational perspective. In this clinical trial, we recorded the evolution of eleven patients diagnosed with schizophrenia and chronic disease who used ALA (100mg / kg) combined with previously prescribed atypical antipsychotic for four consecutive months. At regular intervals, symptoms typical of schizophrenia were assessed using symptom quantification scales (BPRS) and extrapyramidal effects (SAS). We compared cognitive performance at different times (Pre-ALA and Post-ALA) through neuropsychological tests. Oxidative alterations (Glutathione, Nitrite, TBARS / MDA) were measured for evidence of lipid peroxidation. We observed a significant reduction of the negative or disorganized symptoms and of the symptoms of excitation or aggressiveness. There was a significant reduction of extrapyramidal effects after the use of ALA. The performance of working memory was significantly improved at the post-ALA stage. The TBARS / MDA levels had a significant reduction associated with antioxidant action. The results of this study reinforce the therapeutic action of ALA for schizophrenic patients, as well as the transversal research methodology for new drugs involved in the treatment of psychiatric disorders.